ARS Pharmaceuticals (SPRY) Q3 2024 earnings summary

Executive summary

• neffy, a needle-free epinephrine nasal spray, received FDA approval in August 2024 for adults and children ≥30 kg and launched in the US in September; also approved in the EU as EURneffy, with launches in additional markets planned for 2025.

• Strategic licensing agreement with ALK-Abelló grants neffy marketing rights in Europe, Canada, and other regions, bringing $145M upfront and up to $465M in total milestones and royalties.

• Over 5,700 healthcare providers reached, 1,700+ physicians submitted prescriptions, and 1,000+ allergists enrolled in the neffy Experience Program since launch.

• Regulatory submissions ongoing or planned in Australia, China, Japan, UK, and Canada to expand global reach.

• Commercial launch strategy includes direct sales, physician engagement, payer contracting, and patient support programs.

Financial highlights

• Q3 2024 revenue was $2.1M, including $0.6M from neffy product sales and $1.5M from collaboration/milestone revenue.

• Operating expenses for Q3 2024 were $23.8M, with $19.3M in SG&A and $4.4M in R&D.

• GAAP net loss for Q3 2024 was $19.1M, or $0.20 per share; nine-month net loss was $41.9M.

• Cash, cash equivalents, and short-term investments at quarter-end were $204.6M; pro forma cash including ALK payment would be $349.6M.

• Gross margin is high due to initial sales from zero-cost inventory; cost of goods sold was $0.1M in Q3 2024.

Outlook and guidance

• Capital expected to fund operations for at least three years, including further clinical trials and commercial expansion.

• Additional regulatory filings for neffy in Canada, UK, China, Japan, and Australia are planned by year-end 2024.

• Phase 2b trial for chronic spontaneous urticaria to begin dosing in early 2025, with data expected by early 2026.

• Expectation to achieve 60% commercial coverage within six months and over 80% within a year.

• PDUFA target date for neffy 1 mg sNDA set for March 6, 2025.